Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ: IPA )

0.4066 +0.0466 (+12.94%)
Streaming Delayed Price Updated: 12:48 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunoPrecise Antibodies Ltd. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology
From ImmunoPrecise Antibodies
Via Business Wire
ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates
From ImmunoPrecise Antibodies
Via Business Wire
Earnings Outlook For ImmunoPrecise Antibodies
Via Benzinga
‘Baby with the Bathwater’ Biotechs (IPA, NRXP, PRFX, LEXX, LQDI)
Via AB Newswire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 74 companies achieved new lows for the year. 
Via Benzinga
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio
From ImmunoPrecise Antibodies
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023
From IMMUNOPRECISE ANTIBODIES LTD.
Via Business Wire
Earnings Scheduled For December 15, 2022
Companies Reporting Before The Bell • Trinity Biotech (NASDAQ:TRIB) is expected to report quarterly loss at $0.04 per share on revenue of $19.50 million. 
Via Benzinga
IPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments
From ImmunoPrecise Antibodies
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022
Via Benzinga
IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
From ImmunoPrecise Antibodies
Via Business Wire
ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75
From ImmunoPrecise Antibodies
Via Business Wire
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Earnings Scheduled For September 14, 2022
Companies Reporting Before The Bell • ImmunoPrecise Antibodies (NASDAQ:IPA) is projected to report earnings for its first quarter. 
Via Benzinga
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5
From ImmunoPrecise Antibodies
Via Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Earnings Scheduled For July 29, 2022
Companies Reporting Before The Bell • Capital Product Partners (NASDAQ:CPLP) is expected to report quarterly earnings at $1.13 per share on revenue of $72.73 million. 
Via Benzinga
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2
From ImmunoPrecise Antibodies
Via Business Wire
Immunity Focused Biotherapeutic Developer with a Hybrid of Services and Technology for a Wide Range of Applications: ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA)
Via Get News
Topics Artificial Intelligence
Exposures Artificial Intelligence
Small Cap Biotechnology Companies Release Positive Quarterly Results (IPA, AVIR, LQDA, ABSI, APVO)
Via AB Newswire
Biotech Recovery Accelerates These Companies Benefit (IPA, SIGA, MNKD, INO, CTIC)
Via AB Newswire
IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant
From ImmunoPrecise Antibodies
Via Business Wire
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
From ImmunoPrecise Antibodies
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.